Korro Bio Q2 2024 Earnings Report
Key Takeaways
Korro Bio reported a net loss of $21.8 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $187.8 million as of June 30, 2024, providing a cash runway into the second half of 2026.
First-in-human trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of 2024.
Preclinical data presented at ATS demonstrated KRRO-110's ability to correct alpha-1 antitrypsin (AAT) protein resulting in >70% of circulating protein to be M-AAT and concomitantly reducing the Z-AAT protein.
Korro Bio ended the second quarter of 2024 with $187.8 million in cash, cash equivalents and marketable securities.
Cash runway into second half of 2026 to fund anticipated completion of KRRO-110 FIH trial and progress additional pipeline candidates.
Korro Bio
Korro Bio
Forward Guidance
Korro Bio anticipates regulatory filing of KRRO-110 in AATD on track for the second half of 2024, interim Phase 1/2 clinical trial readout for KRRO-110 in ZZ AATD patients anticipated in the second half of 2025 and completion of the Phase 1/2 clinical trial for KRRO-110 expected in 2026.
Positive Outlook
- Regulatory filing of KRRO-110 in AATD on track for the second half of 2024.
- Interim Phase 1/2 clinical trial readout for KRRO-110 in ZZ AATD patients anticipated in the second half of 2025.
- Completion of the Phase 1/2 clinical trial for KRRO-110 expected in 2026.